(−)-Myrtenal

SKU: orb1299390

Description

This small molecule research compound has been shown to reduce hyperglycemia in diabetic rat models. Its mechanism involves Akt-mediated upregulation of GLUT2 transporter expression in skeletal muscle and liver tissues, making it a candidate for investigating glucose metabolism pathways in both in vivo and in vitro experimental systems.

Research Area

Signal Transduction

Key Properties

• CAS Number: 18486-69-6
• MW: 150.22
• Purity: 98.53% (May vary between batches)
• Formula: C₁₀H₁₄O
• SMILES: CC1(C)[C@@H]2C[C@H]1C(C=O)=CC2
• Target: Others,Akt
• Solubility: DMSO:30 mg/mL (199.71 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (13.31 mM)

Bioactivity

• In Vivo:
  Diabetic rats were administered myrtenal (80 mg/kg bw) for a period of 28 days. Diabetic rats showed an increased the levels of plasma glucose, decreased the levels of plasma insulin, down-regulation of insulin receptor substrate 2 (IRS2), Akt and glucose transporter 2 (GLUT2) in liver and insulin receptor substrate 2 (IRS2), Akt and glucose transporter 4 (GLUT4) protein expression in skeletal muscle.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Akt, (1R)-(−)-Myrtenal, (?)-Myrtenal, (−)Myrtenal, (−)-Myrtenal, (−) Myrtenal, diabetic, inhibit, Inhibitor, hyperglycemia, GLUT2, terpene, Protein kinase B, PKB

Compound Identifiers

PubChem CID

1201529